FDA Approves Braftovi and Mektovi for Some Patients with Met

Braftovi (encorafenib) with Mektovi (binimetinib) has been approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the agency announced on Wednesday evening.

Related Keywords

Foundationone Cdx , Chris Boshoff , Pfizer Global Product Development , Pfizer , Drug Administration , Foundationone Liquid , Supplemental New Drug Application , Clinical Oncology , News , Lung Cancer ,